

The American Association of Neurological Surgeons and Congress of Neurological Surgeons

Section on Tumors

Ronald E. Warnick, MD, Editor

Fall 1998

Section on Tumors Officers

CHAIRMAN

Mark Bernstein, MD

PAST-CHAIRMAN

William Chandler, MD

SECRETARY-TREASURER Joseph Piepmeier, MD

ADVISORY BOARD

Mitchel Berger, MD Dennis Bullard, MD Paul Kornblith, MD Timothy Mapstone, MD Robert Morantz, MD Raymond Sawaya, MD Laligam Sekhar, MD Michael Walker, MD

COMMITTEE CHAIRS

Awards

Peter Black, MD Edward Laws, MD

Bylaws

Jack Rock, MD

Education

William Couldwell, MD

International

Armando Basso, MD Nicholas de Tribolet, MD Andrew Kaye, MD Kintomo Takakura, MD David Thomas, MD

Membership

Michael McDermott, MD

Membership Services Anthony Asher, MD

Newsletter

Ronald Warnick, MD

Nominating William Chandler, MD

Program

Michael McDermott, MD Jack Rock, MD James Rutka, MD Ronald Warnick, MD

Research

Roberta Glick, MD

Task Forces

Jack Rock, MD Mark L. Rosenblum, MD

Young Neurosurgeons Nelson Oyesiku, MD

CHAIRMAN'S ADDRESS

Mark Bernstein, MD



The Tumor Section is very excited about our Scientific Program at the upcoming CNS Annual Meeting in Seattle, Washington. We look forward to the program organized by Jack Rock, MD, in particular, sessions on 'Supratentorial Meningiomas: Difficult Problems" and "Epidermoids, Dermoids, and Arachnoid Cysts." As always, we will present awards for the best resident laboratory research paper (Preuss), the best clinical research paper by a practicing neurosurgeon (Mahaley), and the best laboratory research by a neurosurgeon within the first six years of practice (Young Investigator).

Our Section's contributions to the Scientific Program at the 1998 AANS Meeting in Philadelphia, Pennsylvania, were a huge success. The Wednesday afternoon session, Special Course III titled "Surgical Neuro-Oncology–How I Do It", and the Satellite Symposium were given rave reviews by all in attendance. Thanks to James Rutka, MD, for his great work in organizing the Satellite Symposium.

The Glioma Outcomes (GO) project, sponsored by Rhône-Poulenc-Rorer, is well under way with 52 centers registered, 233 patients enrolled, and a plethora of data collected. Many of you are contributing to and will benefit from this project that will introduce an instrument designed to facilitate the prospective collection of outcome data in patients with malignant gliomas. The project will provide a comprehensive outcome study highlighting important quality of life information. Our Section also has finished working on the "Practice Parameters for Low-grade Glioma" (recently published in the June issue of Neurosurgical Focus) and has started the same process for brain metastases.

We also have a number of interesting committee projects under way and, to that end, I would like to thank all of our committee chairs for their hard work. For example, Anthony Asher, MD, is compiling brain tumor information for the Internet, as well as summarizing literature on multidisciplinary neuro-oncology for our members. In addition, Ronald Warnick, MD, has recently completed the analysis of a questionnaire assessing neuro-oncology research opportunities for neurosurgery residents in North America. The results of the survey will be published in the Bulletin.

Special thanks to all of our Tumor Section members for your ongoing interest in and support of the Section. Should you have any inquiries, or input as to how we can improve our Section, please let us know. I look forward to seeing you in Seattle!

In This	Issue
Section Committee Reports	Minutes of the Executive Council Meeting 8
Section Awards	Internet Sites Pertaining to Neuro-Oncology 9
In Brief	Neuro-Oncology Funding Opportunities 9
	Tumor Membership Application 11
Tumor Section-At-A-Glance 6-7	

SECTION COMMITTEE REPORTS

Awards Committee

Peter Black, MD Edward R. Laws, Jr., MD

We are pleased to announce Dr. Byron Young as the recipient of the Mahaley Clinical Research Award; Dr. Bob Carter as the recipient of the Preuss Resident Award and Dr. Eric Elowitz as the recipient of the Young Investigator Award.

International Committee

Kintuomo Takakura, MD, PhD

There will be several Asian meetings related to neuro-oncology in the coming year. They include:

The 7th Japanese Brain Tumor Conference

November 8-10, 1998

Kaga, Japan

Chairman: Professor J. Yamashita

FAX: 81-76-234-4262

The 5th Annual Meeting of the Japanese Society for Neuroendoscopy

November 13-14, 1998

Matsue, Japan

Chairman: Professor K. Moritake

FAX: 81-3-3354-8053

The 9th Meeting of the Japan Society for Hypothalamic and Pituitary Tumors

February 18-19, 1999

Tokyo, Japan

Chairman: Professor A. Teramoto

FAX: 81-3-5685-0986

International Joint Meeting on Skull Base Surgery and Neurosurgical Techniques and Tools

March 22-25, 1999

Osaka, Japan

Chairman: Professor A. Hakuba

FAX: 81-6-647-8085

The 4th International Conference of the Asian Clinical Oncology Society

August 5-7, 1999 Jakarta, Indonesia

Chairman: Dr. Sochartati Gondhowiardjo

FAX: 62-21-315-4175

The 5th Asian-Oceanic International Congress of Skull Base Surgery

November 12-15, 1999

Mumbai, India

Chairman: Dr. K. E. Turel FAX: 91-22-413-2292

Membership Services Committee Report

Anthony Asher, MD

The Membership Services Committee of the AANS/CNS Section on Tumors has partnered with **NEUROSURGERY://DN-CALL®** to develop internet-based resources related to brain tumor research and therapy. The services under development include:

- Expanded lists of neuro-oncology fellowships, funding sources, and meetings of interest;
- Links to related Web sites:
- An online listing of current publications that will be updated monthly. Members will have the opportunity to view a list of new brain tumor publications and book reviews. There also will be an opportunity to order textbooks of interest online;
- An online membership directory that will allow searches by name, institution, or geographical location. Several unique features will be available through the membership directory including direct e-mail, list serve capabilities, and links to member Web sites;
- Negative Trial Survey. A national survey on negative brain tumor trials that will be coordinated by Tom Chen, MD, from UCLA;
- National Cancer Database. Members will have the opportunity to submit brain tumor questions to the National Cancer Database. This service will be coordinated by Herb Engelhard, MD, from Northwestern University;
- A listing of support resources for brain tumor patients and their families;
- A multidisciplinary effort designed to provide a concise summary of literature relevant to neuro-oncology on a quarterly basis. This project will be conducted with the Society for Neuro-Oncology; and
- Links to the Society for Neuro-Oncology Web site and online discussion groups focused on brain tumor diagnosis and treatment.

In the near future, we will be sending all Section members a notice with additional information regarding the membership directory, e-mail services and discussion groups.

We expect that most of these services will be available by fall, 1998. If you do not have e-mail or Internet access, we strongly encourage you to acquire these capabilities soon so that you can take advantage of these new services. Please feel free to contact me, or Allison Casey, N=//DC® Manager, regarding the restructuring of our Web site.

SECTION AWARDS FROM THE 1998 AANS MEETING

Preuss Resident's Research Award Paper

Expression of Growth Factor Receptors in Glioblastoma Multiforme Cell Lines and Tumor Specimens: Results in Ras Activation and Ras-Dependent Tumor Proliferation

Matthias M. Feldkamp, Nelson Lau, Abhjit Guha

Glioblastomas (GBM) express high levels of growth factor receptors, particularly the epidermal growth factor receptor (EGF-R). We have proposed that these receptors activate the Ras pathway in these cells, resulting in Ras-dependent proliferation. The status of EGF-R and PDGF-R was evaluated in five established astrocytoma cell lines (U87, U118, U138, U343, and U373). Levels of activated Ras GTP were measured in these cell lines using a ³²P loading assay. Twenty operative GBM specimens were evaluated for levels of activated Ras GTP using a novel luciferase-based assay. The relevance of Ras activation in cell lines was evaluated using genetic (dominant negative Ras-N17) and pharmacological means (treatment with the farnesyl transferase inhibitor L-739, 749). Activation of downstream mitogenic pathways (MAPK) was evaluated using a myelin basic protein (MBP) kinase assay.

The mean level of Ras GTP in the operative tumor specimens was 1.62 ± 0.62 fmol/5 g DNA, compared to levels of only 0.08 and 0.04 fmol/5 g DNA in two nonneoplastic head injury specimens used as controls. Levels of Ras in the five astrocytoma cell lines were similar to levels in v-H-Ras-transformed murine fibroblasts (RT8 cells), with approximately 30 percent of Ras being in the activated (GTP-bound) form in these cells. Nontransformed human astrocytes also demonstrated lower levels of Ras GTP (11.2% ± 1.1 percent of Ras in GTP-bound form). Direct sequencing of H-Ras and K-Ras in these five astrocytoma cell lines confirmed the absence of oncogenic Ras mutations to explain the high levels of Ras GTP observed. Expression of the truncated EGF-Rp140-EGF-R in U118 cells resulted in higher levels of constitutive Ras GTP, correlating with a twofold proliferative advantage following 14 days in tissue culture. When Ras activity was inhibited using Ras-N17, proliferation and colony formation in soft agar were reduced to less than 50 percent of control cells, correlating with 50 percent reductions in Ras GTP levels and 50 percent reduction in MAPK activity. Pharmacological Ras inhibition in U87 cells using the farnesyl transferase inhibitor L-739, 749 resulted in 48 percent reduction in proliferation (p = 0.0063 by paired t-test), even at low doses (10³ M) over short periods (12 days treatment).

These experiments confirm the relevance of Ras-mediated signaling in the molecular pathogenesis of GBMs. Those GBMs expressing the truncated constitutively activated EGF-Rp140-EGF-R demonstrate even higher levels of Ras activation. Activation of the Ras pathway is critical in the proliferation of these tumors, as evidenced by genetic manipulation (using Ras-N17) as well as pharmacological inhibition (with L-739, 749). While oncogenic mutations of Ras are not present in astrocytomas, the overexpression of surface receptors results in functionally important activation of the Ras pathway, making such tumors potentially amenable to novel pharmacological agents which specifically target the Ras pathway.

Mahaley Clinical Research Award Paper

Endoscopic Transsphenoidal Resection of Pituitary Tumors Prem Pillay, D. Sethi

We report our long-term experience with endoscopic transsphenoidal resection of pituitary tumors in 172 patients followed for a mean of 3.1 years. Our technique makes use of 4-mm diameter nasal endoscopes (Nos. 00, 300, 700, 1200) to define a surgical approach which is through a 10-mm septal incision and is transnasal, transseptal (uniseptal dislocation), and transsphenoidal. Using video-endoscopy (3 chip-camera) and functional endoscopic sinus surgery instruments, we expose the sphenoid sinus including the sella turcica. Endoscopic surgery allows a well-illuminated, magnified panoramic view of the sphenoid cavity and sellar contents. Tumor removal, particularly in the suprasellar and lateral sellar/juxta cavernous sinus location, is carried out under direct vision using 2-mm endoscopes.

Radical tumor removal was possible in 85 percent of pituitary macroadenomas with suprasellar extension (101 of 172 patients). Normalization of hormonal levels was achieved long term in 92 percent of prolactinomas, 84 percent of growth hormone-producing microadenomas, and 83 percent of ACTH-producing microadenomas. Eight patients had transient diabetes insipidus, 2 had post-operative CSF rhinorrhea, and 2 required evacuation of postoperative intrasellar hematomas. The average postoperative stay was 2 days in 85 percent of patients. Endoscopic transsphenoidal resection of pituitary tumors is now our technique of choice in the treatment of pituitary tumors.

Young Investigator Award Paper

Mechanisms of p53-Induced "Bystander Effect" in Tumor Suppression: 1. Evidence of Angiogenesis Inhibition in Vivo After Intratumoral Injection of p53/Cationic Liposome Complexes Michael Hsiao, Victor C. Tse, Linnea Kim, Gerald D. Silverberg

The aim of this study was to explore the bystander effect of wtp53 transfection of glioblastoma cell growth suppression. A p53-mediated bystander effect was described while we were investigating the functions of the p53 gene in suppressing rat RT2 glioblastoma tumor growth in situ. This bystander effect of the p53 gene showed promise compared to apoptosis and cell cycle arrest, particularly since high transfection or infection efficiency is very difficult to achieve using the vectors currently available.

An RT2 glioblastoma model was established. Subcutaneous RT2 tumors were intratumorally challenged with p53/liposome complexes and the pattern of vascular growth studied. The results showed a 51 percent reduction of tumor growth by the p53 gene compared to vector control. There was an 81 percent reduction in arterial branches to the p53 infected tumors and a 75 percent reduction in capillary density within the tumors. Further, there was a 95 percent reduction

continued on page 4

SECTION AWARDS FROM THE 1998 AANS MEETING (continued from page 3)

in lung metastases in the p53-treated group compared to controls. One hundred percent of the mice survived more than 50 days after p53/liposome injections. In comparison, all of the mice challenged with vector/liposome died within 15 days. The p53 transgene expression was found in only about 20 percent of the tumor cells. However, significant necrosis was found at the center of the tumors and no apoptosis detected after injecting p53/liposome complexes.

Our results demonstrated that the p53 transfection/expression by the intratumoral injections of p53/liposome complexes resulted in significant tumor suppression and prolonged animal survival. We show in these experiments that inhibition of angiogenesis triggers the bystander effects leading to massive necrosis, reduced growth, and inhibition of metastasis.

Newsletter items may be sent to:

Ronald E. Warnick, MD
Department of Neurosurgery
University of Cincinnati Medical Center
231 Bethesda Avenue
Cincinnati, OH 45267-0515

Phone: (513)-558-3179 Fax: (513)-558-0886 E-mail: nsgymd@aol.com

CNS Meeting Offers Real-Time Streaming Video

The Congress of Neurological Surgeons (CNS) is pleased to offer real-time video broadcasts of its Annual Meeting General Scientific Sessions via the official AANS/CNS Web site — **NEUROSURGERY://DN-CALL®**. To access **NEUROSURGERY://DN-CALL®**, go to http://www.neurosurgery.org and click on "Professional Pages." On the welcome page, select the "Live Video from the CNS Meeting" link. To view the presentations, you will need a Real Media plug-in. A free download is available from the Real Media Web site at http://www.real.com.

If you are unable to access the Web site during the broadcasts, the talks, as well as a bevy of other presentations, will be available as archived video files. For questions or concerns regarding this service, e-mail us at info@neurosurgery.org.

Live Presentations

Monday, October 5, 1998—General Scientific Session I

7:30-7:50 am	8:50-9:50 ам	11:15-11:45 ам
Principals of Surgical Localization Michael Apuzzo, MD	Honored Guest Presentation — Technical Innovations and Everyday Practice John M. Tew, Jr., MD	Presidential Address William A. Friedman, MD

Live Presentations

Tuesday, October 6, 1998 — General Scientific Session II

8:10-8:30 AM	8:50-9:10 am	11:20-11:45 ам
The Neurosurgeon's Role in Triage and Acute Management Raj Narayan, MD	Contemporary Treatment Paradigms — Spinal Injury Mark Hadley, MD	Neurosurgeons at the Forefront— Prevention, Treatment, Research and Legislation Lawrence Pitts, MD

Should you need technical support, contact:

Ivan Ewert
Interactive Media Designer, AANS
Phone: (847) 692-9500 (ext. 560)

E-mail: ife@aans.org



American Brain Tumor Association

ABTA Raises Funding for Fellowship Awards and Offers New Grant

The American Brain Tumor Association (ABTA) proudly announces a monetary increase for their highly coveted Post-Doctoral Basic Research Fellowships commencing July 1, 1999. These fellowships will be two \$60,000 awards: \$30,000 per annum for two years. Qualified Fellowship applicants must be MDs within two years of residency completion, or PhDs with no more than 30 months postdoctoral laboratory experience.

ABTA also is pleased to offer a one-year \$50,000 Translational Brain Tumor Research Grant. In this context, translational is defined as preclinical research intended to evaluate the therapeutic potential of recent discoveries in the basic mechanisms of either brain tumor pathogenesis or experimental therapeutics. Human studies are excluded. Qualified grant applicants must be MDs who are up to five years postresidency and have attained junior faculty to assistant professor stature, or PhDs with no more than five years postdoctoral laboratory experience.

Eligible applicants for both awards must be citizens or permanent residents of the United States or Canada. Applicants for 1999-2001 fellowships and 1999-2000 grants are now being accepted. For more information, contact The American Brain Tumor Association, phone (847)827-9910, e-mail Info@abta.org.

National Brain Tumor Foundation

Existing Research Projects Funded by NBTF

Two researchers with the North American Brain Tumor Consortium are the recipients of the National Brain Tumor Foundation's (NBTF) 1998 grant program. Each year, NBTF awards \$25,000 to two investigators who propose innovative brain tumor research projects.

University of California (San Francisco) researcher, Burt Feuerstein, MD, will use his grant to look into the genetic makeup of glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). Previous work has shown that mutations in the tumor suppressor gene p53 occur in about half of all glial tumors. Patients who have mutations in p53 seem to do better than those who do not. Dr. Feuerstein has identified a chromosomal abnormality that is both a poor predictor in patients with AA and an indicator of radiation resistance in patients with GBM. This study will ask whether p53 mutations occur simultaneously in patients with this chromosomal abnormality or not. The results of this study may help identify those patients who will respond to radiation and those who will survive the longest. The plan is to eventually divide these patients into treatment groups for the best possible treatment outcomes.

John Kuhn, MD, of the University of Texas Health Science Center (San Antonio), will use his NBTF grant to study the effects of antiseizure medications on the chemotherapy drug CPT-11. This drug has already been approved for use in the treatment of colorectal cancer and has shown promising activity in a phase I brain tumor clinical trial. Preliminary results indicate that standard antiseizure medications may alter the toxicity of CPT-11. Dr. Kuhn intends to study the effects of antiseizure medications on the metabolism and biology of CPT-11. This will help in the development of future trials with CPT-11 in combination with other active agents.

New National Brain Tumor Foundation Publications

In NBTF's ongoing effort to provide up-to-date information to patients, family members and health professionals, we are proud to announce the following new publications:

- Fact Sheet: New Chemotherapy Drugs for Brain Tumor Patients
- Fact Sheet: Gene Therapy: A New Experimental Treatment for Brain Tumors
- Understanding Brain Tumors: Glioblastoma Multiforme.

To request your copy, please call NBTF at (800) 934-CURE (2873).

1998 CNS Annual Meeting Tumor Section—At—A—Glance October 3—8 Seattle, Washington

Saturday, October 3—Practical Courses

8 am-Noon

003 Transsphenoidal Surgery

Course Directors: Warren R. Selman, Mary Louise Hlavin

Faculty: William Couldwell, Gail Rosseau, Gerard Rodziewicz

010 Cortical Mapping for Tumor Resection

Course Directors: Mitchel S. Berger, Nicholas Barbaro Faculty: Howard Rowley, Carl Sartorius

Sunday, October 4-Practical Courses

8 AM-NOON

020 Temporal Bone–Acoustic Surgery

Course Director: Steven L. Giannotta

Faculty: John D. Day, Carl Heilman, Anil Nanda

025 Neurosurgical Navigation-Cranial

Course Directors: Isabelle Germano, Barton Guthrie

Faculty: Gene Barnett, John Adler, Robert Maciunas,

William Tobler, Haring J.W. Nauta, Richard Bucholz

029 Lateral Skull Base Operative Approaches

Course Director: Donald C. Wright

Faculty: Chandranath Sen, Duc Duong, Brian Sullivan,

Timothy Burke, Charles Rosen, Scott Hanson

1-5 PM

036 Anterolateral Skull Base Operative Approaches

Course Directors: Harry R. Van Loveren, Jeffrey Keller

Faculty: Rashid Jaujua, Abhay Sawan, Khaled Abdel Aziz, Jae Min

Kim, Michael Chicoine, Mario Zuccarello

037 Stereotactic Radiosurgery

Course Director: Douglas S. Kondziolka

Faculty: Christopher Duma, Eben Alexander, III, Alan Hamilton,

John Adler, Bruce Pollock

Monday, October 5-Luncheon Seminars

Noon-2 PM

133/134 Mapping of the Cerebral Cortex

Moderator: G. Ojemann

Faculty: Y. Comair, R. Marino, A. Wyler, E. Zusman

137/138 Choosing a Skull Base Approach

Moderator: O. Al-Mefty

Faculty: C. Sen, J. Robertson, R. Maciunas, J. Dellashaw

143/144 Functional Brain Imaging

Moderator: R. Cosgrove

Faculty: M. Schlosser, W. Hall, P. Kelly

145/146 Surgery and Radiosurgery in the Management of Intracranial

Metastatic Disease

Moderator: D. Bullard

Faculty: J. Buatti, E. Alexander, III, G. Harsh, IV, R. Spiegelmann

147/148 Craniopharyngioma/Controversies in Management: (Point/Counterpoint)

Moderator: F. Boop

Faculty: J. Wisoff, R. Sanford, J. Rutka

Scientific Program

2-5:30 РМ

Supratentorial Meningiomas: Difficult Problems

Moderators: Jack Rock, Mark Bernstein
2-2:25 PM The Venous System Jacques Brotchi

2:25-2:50 PM Management of Recurrent and

En Plaque Meningiomas

Robert Ojemann

2:50-3:30 PM Oral Posters

3:30-4 PM Coffee Break

4-5:30 PM Open Papers (732-741)

Preuss Award

732 A Novel Secreted Form of the Angiogenesis Inhibitor Endostatin Prolongs Survival in Mice Inoculated With U-87 Tumor Xenografts. *Bob S. Carter, Thomas Boehm, Judah Folkman, Richard Mulligan.*

Young Investigator Award

733 Boron Neutron Capture Therapy of Glioblastoma Multiforme at Brookhaven National Laboratory: Results of the Phase I/II Trial. Eric H. Elowitz, Jacek Capala, Manjeet Chadha, Douglas S. Cohen, Jeffrey A. Coderre, Z. Diaz, Daryl D. Joel, M. Shady, George W, Tyson, Arjun D. Chanana.

734 Central Neurocytoma: An Analysis of the Effects of Surgery and Radiotherapy — A Review of 225 Cases. *Michael K. Landi, Walter Grand, Mary Duffy Fronckowiak, Veetai Li, Robert J. Plunkett.*

735 Morbidity and Survival After BCNU Wafer Implantation for Recurrent Glioblastoma: A Retrospective Case Matched Cohort Series. *Brian R. Subach, Timothy F. Witham, Douglas Kondziolka, L. Dade Lunsford.*

736 Development of Anticancer Vaccines for Brain Tumors. Walter A. Hall, Margaret A. Wallenfriedman, Walter C. Jean, Walter C. Low.

737 Beneficial Effects of the Radioprotectant 21 – Aminosteroid U-74389G in a Radiosurgery Rat Malignant Glioma Model. *Douglas Kondziolka, Yoshimasa Mori, A. Julio Martinez, Mark Mclaughlin, John C. Flickinger, L. Dade Lunsford.*

738 Hyperostosis Associated With Meningioma of the Skull Base: Secondary Changes or Tumor Invasion. *Daniel R. Pieper, Ossama Al-Mefty, Yusei Hanada, David Buechner.*

739 In Vitro Assessment of Cell Migration in Human Gliomas. Nikolai J. Hopf, Tim Demuth, Axel Perneczky.

740 High-Dose Proton and Photon Radiation Therapy in the Management of Atypical and Malignant Meningiomas. Eugen Hug, Alexander De Vries, John Munzenrider, Tessa Hedley-Whyte, Robert Ojemann.

741 Management of Cranial Chordomas. Alfred P. Bowles, Jr.

Tuesday, October 6-Luncheon Seminars

Noon-2 PM

207/208 Management of Spinal Column and Cord Neoplasms

Moderator: D. Cahill

Faculty: C. Branch, P. McCormick, P. Hitchon, Joan O'Shea

227/228 Posterior Fossa and Brain Stem Tumors in Pediatric Patients

Moderator: T. Mapstone

Faculty: C. Raffel, I. Pollack, J. Patronio, P. Mickle

235/236 Skull Base Surgery: Complications and How to Avoid Them

Moderator: L. Sekhar

Faculty: F. Umansky, D. Wright, J. Chandler

237/238 Acoustic Schwannomas Controversies (Point/Counterpoint)

Moderator: R. Ojemann

Faculty: S. Giannotta, J. Lee, S. Haines, M. Mayberg

239/240 New Approaches to Pituitary Adenomas

Moderator: C. Wilson

Faculty: E. Laws, Jr., N. Oyesiku, M. Hadari

241/242 Surgical Approaches to Neoplasms of the Lateral and Third Ventricles

Moderator: A. Rhoton, Jr.

Faculty: M. Apuzzo, G. Yasargil, P. Black

245/246 Intraoperative Imaging

Moderator: W. Selman

Faculty: S. Grady, A. Parent, J. Thomas, P. Stieg

Scientific Program

2-5:30 РМ

Epidermoids, Dermoids and Arachnoid Cysts

Moderators: Jack Rock, Joseph Piepmeier
2–2:25 PM Epidermoids and Dermoids Donlin Long
2:25–2:50 PM Arachnoid Cysts Felix Umansky

2:50–3:30 PM Oral Posters 3:30–4 PM Coffee Break

4–5:30 PM Open Papers (772-781)

Mahaley Award

772 A Randomized Trial of Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain. *Byron Young, R. A. Patchell, R. J. Yaes, L. Beach, R. J. Kryscio, D. G. Davis, P. A. Tibbs.*

773 Melanoma Metastatic to Brain: Prognostic Factors and Results of Treatment. Ian E. Mccutcheon, Emilio Nardone, Jennifer Luiz, Kenneth Hess, Carl Plager.

774 Stereotactic Surgical Management of Non-Contrast Enhancing Glial Tumors Achieves Better Disease Control. *Jeffrey S. Weinberg, George I. Jallo, John G. Golfinos, Douglas C. Miller, Patrick J. Kelly.*

775 The Clinical Utility of Functional MRI Assessment in Operative Planning for Patients With Neoplasms Involving Language Areas. *Brian K. Pikul, Susan Y. Bookheimer, Keith L. Black, Matthew Quigley, Alexander Anetakis, Amr Elrifai, Shalmon Kalnicki. Discussant: Philip Gutin.*

776 Somatosensory Evoked Potentials for Cortical Mapping in Patients With Paracentral Tumors. *Ian E. Mccutcheon, Salim Kanaan, Suresh Sankhla, Bartlett A. Moore III, Franco Demonte, Raymond Sawaya.*

777 Radiosurgery for Brain Metastases: Increasing the Treatment Volume Significantly Increases Therapeutic Yield. *Roberto Spiegelmann, Yevgeni Pevzner, Rafael Pffefer.*

778 Brachytherapy. Patrick Hitchon, Pamela Schneider, Jim Torner, Marge Rogers, John Vanglider.

779 Cortical Intraoperative Stimulation in Brain Tumors as a Tool to Evaluate Spatial Data From Functional MRI. F. E. Roux, K. Boulanouar, J. P. Ranjeva, M. Tremoulet, C. Manelfe, J. Sabatier, I. Berry.

780 Surgery for Pineal Region Tumors: Results, Complications and Outcomes in 55 Patients. Steven G. Ojemann, Susan Chang, Mitchel Berger.

781 Biodegradable Polymeric Wafers Impregnated With Adriamycin for the Treatment of Intracranial Neoplasms. Victor L. Perry, Mark Watts, Maciej Lesniak, Martin Burke, Betty M. Tyler, Henry Brem.

Wednesday, October 7-Luncheon Seminars

Noon-2 PM

329/330 Low-Grade Cerebral Gliomas Management Controversies: (Point/Counterpoint)

Moderator: J. Piepmeier

Faculty: M. Schulder, Z. Ram, P. Gutin, M. Bernstein

331/332 Management of Clivus, Petrous and Foramen Magnum Tumors

Moderator: O. Al-Mefty

Faculty: K. Gibbons, J. Bruce, M. Shah, A. Ogawa

333/334 Pitfalls and Complications in Cavernous Sinus Surgery

Moderator: L. Sekhar

Faculty: H. Van Loveren, T. Fukoshima, G. Rosseau, Joung Lee

337/338 Gene Therapy Update
Moderator: J. Markert

Faculty: C. Raffell, N. Chiocca, L. Chin

341/342 Advances in Glioma Management

Moderator: R. Sawaya

Faculty: K. Black, M. McDermott, D. Benzil, M. Berger

Scientific Program

2-5:30 РМ

When Not to Operate

Moderators:	Stephen Haines, Richard Winn	
2-2:15 РМ	The Decision Making Process	Stephen Haines
2:15-2:35 PM	Congenital Disorders	Joe Madsen
2:35-2:55 PM	Intracranial Aneurysms and	
	Vascular Malformations	Richard Winn
2:55-3:10 РМ	Carotid Occlusive Disease	David Piepgras
3:10-3:30 РМ	Brain Tumors	Mitchel Berger
3:30-4 PM	Coffee Break	
4-4:30 РМ	Spinal Disorders	Donlin Long
4:30-5:10 РМ	Online Case Presentations to	ME
	Faculty	Stephen Haines
5:10-5:30 РМ	Legal Implications of	
	Nonoperative Decisions	W. Ben Blackett

Photos courtesy of the Seattle & King County Convention & Visitors Bureau.

MINUTES OF THE EXECUTIVE COUNCIL MEETING

AANS/CNS Section on Tumors April 27, 1998 Philadelphia, Pennsylvania

The Executive Council of the AANS/CNS Section on Tumors was called to order at 1 PM. In attendance at the Meeting were Doctors Mark Bernstein (Chairman), Joseph Piepmeier, Peter Black, Jack Rock, William Couldwell, Michael McDermott, Anthony Asher, Ronald Warnick, Kevin Lillehei, William Chandler, Nelson Oyesiku, James Rutka, Roberta Glick, Mitchel Berger, Paul Kornblith and Michael Walker.

Minutes

The minutes from the Executive Council Meeting held at the 1997 CNS Meeting were approved.

Committee Reports

Treasurer's Report

The Section on Tumors remains in very sound financial shape. As discussed at the last Executive Council Meeting, the Section has invested \$50,000 into a portfolio managed by the AANS. It is anticipated that this portfolio will generate a significant increase in return over our current account, and that these new funds could serve as a source of revenue for additional projects.

Awards Committee

Award winners at the 1998 AANS Meeting were:

Preuss Award Matt Feldkamp, MD
Mahaley Clinical Research Award Prem Pillay, MD
Young Investigator Award Michael Hsiao, MD
National Brain Tumor
Foundation Award Iames Ruska, MD, Ph

Foundation Award James Rutka, MD, PhD Farber Award Mark Israel, MD

Bylaws Committee

Jack Rock, MD, presented options for establishing a quorum at business meetings for membership determination. The consensus was that five was an appropriate number based on the relative proportion required for the parent organizations. Lists of potential new members can be mailed to the membership.

Education Committee

William Couldwell, MD, presented an extensive list of neuro-oncology fellowships offered in the U.S. and Canada. This data will be used in the selection criteria for evaluating fellowships. It was suggested that this list be published in the *Journal of Neuro-Oncology*, added to the **NEUROSURGERY://ON-CALL®** Web site and coupled with information on available fellowship funding sources.

International Committee

No report was submitted.

Membership Committee

Our Section's current membership totals 599 and, since the 1997 CNS meeting, there have been 44 new applications. In an effort to keep membership numbers up, Michael McDermott, MD, along with Chrystine Hanus (AANS Membership Manager), sent a letter to each department chair inviting them to circulate applications among their faculty and residents. In addition, a member registration booth will be set up at the Tumor Symposium following the AANS Annual Meeting. To submit a membership application, one must be a candidate AANS member or a resident CNS member.

Membership Services Committee

Anthony Asher, MD, proposed that we work with the editorial board of **NEUROSURGERY://DN-CALL®** to create a "Comprehensive Guide to Services for Members" on our Web site. The guide, which would include fellowship listings, recent publications in neuro-oncology, a membership and e-mail directory, research protocols, support services, and awards and grants provided by the AANS/CNS Section on Tumors, was strongly supported. In addition, it was suggested that a review of scientific publications highlighting neuro-oncology issues be conducted and submitted at the next Executive Council Meeting.

Newsletter Committee

In an effort to reach a larger audience, our newsletter will be distributed to all Tumor Section members, candidate members of the AANS and CNS and posted on our Web site. Additional features such as research opportunities, bylaws, treatment guidelines, fellowships, "Ask the Expert," and "You Make the Diagnosis" also were suggested.

Program Committee

Jack Rock, MD, will serve as the CV Section program chairman of this year's CNS Annual Meeting in Seattle, Washington; Ronald Warnick, MD, will cover the 1999 AANS Annual Meeting in New Orleans, Louisiana; and Michael McDermott, MD, will provide for the 1999 CNS Annual Meeting in Boston, Massachusetts. There was a discussion on various ways to increase the number of accepted abstracts and number of participants; however, the limitations on program length and format are set by the parent organizations and do not allow much room for change.

Research Committee

Roberta Glick, MD, presented a list of opportunities for research funding, highlighted the impact of managed care on research, listed new NIH grant review criteria, identified Web sites focused on clinical trials, and gave an update on grant opportunities specific for neuro-oncology. Assistance from the Radiation Therapy Oncology Group (RTOG) was addressed and it was the consensus that the RTOG is

continued on page 9

MINUTES (continued from page 8)

not user friendly. In addition, names of neurosurgeons for NIH study sections were solicited and results of the survey on research opportunities will be mailed to department heads.

Task Forces Guidelines

A new task force for the development of the "Single Brain Metastasis Guidelines" has commenced under the leadership of Dr. Rock, and the "Low-grade Glioma Guidelines" were finished in June 1998.

Other Business

GO Project

To date, 41 centers and 100 patients have taken part in the Glioma Outcomes project.

Satellite Symposium

A total of 170 people pre-registered for the 3rd Satellite Symposium that immediately followed the 1998 AANS Annual Meeting at the Wyndham Franklin Hotel. In addition, there were participants that registered on-site. The next Satellite Symposium, proposed for the CNS Annual Meeting in Boston, Massachusetts, still needs to be explored.

Thieme Neuro-Oncology Book

The text, edited by Doctors Bernstein and Berger, will include chapters primarily provided by members of the AANS/CNS Section on Tumors. Manuscripts were due by July 1, 1998.

Criteria for New Sections

A proposal for a Skull-Base Surgery Section was presented. The proposal, which generated both controversy and discussion, addressed the impact it will have on existing Sections. Dr. Bernstein will prepare a detailed report on the nature of this discussion for Stan Pelofsky, MD, Secretary of the AANS.

Journal of Neuro-Oncology

The question was raised, if the *Journal of Neuro-Oncology* significantly reduces its subscription rate, would our Section make the *Journal* part of its membership dues. The consensus was to mail a questionnaire to the membership to determine their wishes regarding making this optional or mandatory.

The meeting was adjourned at 2:30 PM.

Respectfully submitted,

Joseph Piepmeier, MD Secretary-Treasurer AANS/CNS Section on Tumors

NEURO-ONCOLOGY ON THE WEB

A number of neuro-oncology Internet resources are now available to investigators, physicians, and patients. They include:

Human Genome Project

http://www.ornl.gov/TechResources/Human_Genome research.html

National Library of Medicine (NLM)

http://www.nlm.nih.gov/databases/freemedl.html

American Brain Tumor Association http://www.abta.org

Brain Tumor Foundation of Canada http://www.btfc.org

National Brain Tumor Foundation http://www.braintumor.org

Pediatric Brain Tumor Foundation of the United States http://www.ride4kids.org

The Brain Tumor Society http://www.tbts.org

Clinical Trials and Noteworthy Treatments for Brain Tumors http://virtualtrials.com

NEURO-ONCOLOGY FUNDING OPPORTUNITIES

Current funding sources (and phone numbers) relevant to brain tumor research include:

AANS Young Investigator Award: (847) 692-9500

American Brain Tumor Association: (847) 827-9910

American Cancer Society: (404) 329-7612

American Institute for Cancer Research: (202) 328-7744

Cancer Control Research Program-NIH/NCI: (301) 496-8520

Cancer Research Foundation of America: (703) 836-4412

Fogarty International Center: (301) 496-1653

National Brain Tumor Foundation: (415) 284-0208

Pfizer Postdoctoral Fellowships: (800) 201-1214

Sloan Basic Research Fellowships: (212) 649-1649

Small Business Innovative Research: (301) 206-9385

U.S. Department of Health and Human Services-NINDS: (301) 496-9248

Fall 1998

Tumor Section Newsletter 9

continued from page 5

NBTF Teleconference: When Your Child has a Brain Tumor

NBTF and Cancer Care, Inc. will be teaming up with The Children's Brain Tumor Foundation to sponsor a very special teleconference, "When Your Child has a Brain Tumor: Latest Treatment Options in Surgery and Chemotherapy." The teleconference will feature presentations by Carolyn Russo, MD, a pediatric neuro-oncologist from the University of California (San Francisco); Stanford Healthcare, and Jeffrey Wisoff, MD, a pediatric neurosurgeon from New York University Medical Center. This teleconference is one in a continuing series sponsored by Cancer Care, NBTF and will take place on Wednesday, December 16, 1998, from 1–2 PM (Eastern Standard Time) and is sponsored by an educational grant from Rhône-Poulenc Rorer.

To register, send your name, address, city, state, zip code and telephone number with area code to Carolyn Messner, ACSW (Children's BT Teleconference) Cancer Care, Inc., 1180 Avenue of the Americas.

Teleconference on Seizures

Understanding and treating seizures is a major issue for many brain tumor patients and their loved ones. In order to address this need, NBTF and Cancer Care, Inc. sponsored a spring teleconference, "Understanding Seizures—Management and Treatment". The teleconference was presented by Timothy Cloughesy, MD, Director of the Neuro-Oncology Program at the UCLA School of Medicine and listed as one of the best doctors in Los Angeles by *Los Angeles Magazine*, and he delivered useful information on dealing with seizures. To view this teleconference, visit their Web site at http://www.braintumor.org.

North American Brain Tumor Coalition

The North American Brain Tumor Coalition (NABTC) is a network of eight charitable organizations dedicated to eradicating brain tumors. The member organizations of the Coalition have awarded over \$18 million in private funds for research related to brain tumors. The Coalition also represents the interests if its constituency by raising public awareness of brain tumors and by advocating for increased research funding, access to specialized care and other issues affecting brain tumor patients.

Since its inception in 1991, the Coalition has established a strong public policy voice on behalf of children and adults with brain tumors. NABTC representatives have testified before Congress in favor of increased biomedical research funding and ready access to new drugs and therapies. The Coalition also participates in meetings on biomedical research and health care delivery at the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and other federal agencies, and collaborates with other organizations representing patients with serious and life-threatening illnesses. Member organizations include:

Acoustic Neuroma Association of Canada
American Brain Tumor Association
Brain Tumor Foundation of Canada
Children's Brain Tumor Foundation
National Brain Tumor Foundation
Pediatric Brain Tumor Foundation of the United States
The Brain Tumor Society
The Preuss Foundation



THE AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS



There is still time to register for
Minimally Invasive Neurosurgery: Neuroendoscopy — Hands On. October 30-31, 1998, Cleveland, Ohio
Course Chairman: Alan R. Cohen, MD

Don't miss out on this excellent opportunity for one-on-one instruction with expert faculty.

This course will give you a comprehensive review of endoscopy and its expanding role in neurosurgery. Hands-on instruction utilizing cadaveric materials allows you to gain expertise in handling a variety of neuroendoscopes for a broad range of procedures, including endoscopic management of ventricular cysts and tumors. You'll also participate in interactive discussions and reviews of video demonstrations about neuroendoscopic procedures.

For more information, call the AANS Professional Development Department at (847) 692-9500, or e-mail us at info@aans.org.

Other educational opportunities for 1998 include:

Neurosurgery Review by Case Management Oral Board Preparation November 8-10 Houston, Texas


The AANS wishes to acknowledge our Professional Development Educational Partners for their generous support of medical education.













APPLICATION FOR MEMBERSHIP



Section on Tumors of The American Association of Neurological Surgeons and Congress of Neurological Surgeons



Name:		
Home Address:		
Home Phone Number:		
Business Address:		
Business Phone Number:		
Fax Number: E-mail:		
I wish to apply for:		
☐ Active Membership ☐ International Membership ☐ Resident Membership*		
*If applying for Resident Membership please have Program Director forward confirmation of your resident status.		
Program: Year of anticipated completion		
Director:		
Are you a member of:		
The American Association of Neurological Surgeons? Yes No		
☐ Active ☐ Active (Foreign) ☐ Active (Provisional) ☐ Associate		
☐ Candidate ☐ International Associate ☐ Honorary ☐ Lifetime		
Congress of Neurological Surgeons?		
☐ Active ☐ Honorary ☐ International ☐ Resident ☐ Senior		
Are you currently involved in active brain tumor research?		
Clinical:		
Basic:		

Please send your complete application and curriculum vitae to:

Michael W. McDermott, MD University of California, San Francisco 533 Parnassus Ave., U-126 San Francisco, CA 94122-2722

AANS/CNS Section on Tumors

22 South Washington Street Park Ridge, Illinois 60068-4287 FIRST CLASS
U.S. POSTAGE
PAID
Des Plaines, IL
Permit No. 329